hengrui glp-1 China Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) China's Hengrui Grants Global Rights

If you miss a dose, there are simple rules to follow: If you remember within four days, take the missed dose as soon as possible and then go back to your normal weekly schedule

Miguens-Gomez et al 2021)

In the SURMOUNT-1 trial, tirzepatide produced average weight reductions of 15.0%, 19.5%, and 20.9% at studied doses compared with 3.1% with placebo over 72 weeks

[2] The takeaway for anyone interested in gut health is simple but powerful: because L-cells respond to signals arriving from the gut lumen, the environment inside your intestine including the composition and activity of your microbiome is directly upstream of how much GLP-1 gets made

Like any medication, they carry risks, but most are mild and manageable